Table 1.
A list of 50 COVID-19 vaccines that have been approved for use in 201 countries.
| Vaccine Name |
Manufacturer | Type of Vaccine |
Approved Status |
Number of Completed Clinical Trails |
Granted EUL by WHO |
|---|---|---|---|---|---|
| Zifivax | Anhui Zhifei Longcom | Protein Subunit | Approved in 4 countries | 21 trials in 5 countries | No |
| Noora vaccine | Bagheiat-allah University of Medical Sciences | Protein Subunit | Approved in 1 country | 3 trials in 1 country | No |
| Corbevax | Biological E Limited | Protein Subunit | Approved in 2 countries | 7 trials in 1 country | No |
| Abdala | Center for Genetic Engineering and Biotechnology (CIGB) | Protein Subunit | Approved in 6 countries | 5 trials in 1 country | No |
| Soberana 02 | Instituto Finlay de Vacunas Cuba | Protein Subunit | Approved in 4 countries | 7 trials in 2 countries | No |
| Soberana Plus | Instituto Finlay de Vacunas Cuba | Protein Subunit | Approved in 2 countries | 5 trials in 1 country | No |
| V-01 | Livzon Mabpharm Inc | Protein Subunit | Approved in 1 country | 7 trials in 3 countries | No |
| MVC-COV1901 | Medigen | Protein Subunit | Approved in 4 countries | 15 trials in 4 countries | No |
| Recombinant SARS-CoV-2 Vaccine (CHO Cell) | National Vaccine and Serum Institute | Protein Subunit | Approved in 1 country | 3 trials in 2 countries | No |
| Nuvaxovid | Novavax | Protein Subunit | Approved in 40 countries | 22 trials in 14 countries | Yes |
| IndoVac | PT Bio Farma | Protein Subunit | Approved in 1 country | 4 trials in 1 country | No |
| Razi Cov Pars | Razi Vaccine and Serum Research Institute | Protein Subunit | Approved in 1 country | 5 trials in 1 country | No |
| VidPrevtyn Beta | Sanofi/GSK | Protein Subunit | Approved in 30 countries | 3 trials in 2 countries | No |
| COVOVAX (Novavax formulation) | Serum Institute of India | Protein Subunit | Approved in 6 countries | 7 trials in 3 countries | Yes |
| SKYCovione | SK Bioscience Co Ltd | Protein Subunit | Approved in 1 country | 7 trials in 6 countries | No |
| TAK-019 (Novavax formulation) | Takeda | Protein Subunit | Approved in 1 country | 3 trials in 1 country | No |
| SpikoGen | Vaxine/CinnaGen Co. | Protein Subunit | Approved in 1 country | 8 trials in 2 countries | No |
| Aurora-CoV | Vector State Research Center of Virology and Biotechnology | Protein Subunit | Approved in 1 country | 4 trials in 1 country | No |
| Razi Cov Pars | Razi Vaccine and Serum Research Institute | Protein Subunit | Approved in 1 country | 5 trials in 1 country | No |
| VidPrevtyn Beta | Sanofi/GSK | Protein Subunit | Approved in 30 countries | 3 trials in 2 countries | No |
| COVOVAX (Novavax formulation) | Serum Institute of India | Protein Subunit | Approved in 6 countries | 7 trials in 3 countries | No |
| SKYCovione | SK Bioscience Co Ltd | Protein Subunit | Approved in 1 country | 7 trials in 6 countries | No |
| TAK-019 (Novavax formulation) | Takeda | Protein Subunit | Approved in 1 country | 3 trials in 1 country | No |
| SpikoGen | Vaxine/CinnaGen Co. | Protein Subunit | Approved in 1 country | 8 trials in 2 countries | No |
| Aurora-CoV | Vector State Research Center of Virology and Biotechnology | Protein Subunit | Approved in 1 country | 2 trials in 1 country | No |
| EpiVacCorona | Vector State Research Center of Virology and Biotechnology | Protein Subunit | Approved in 4 countries | 4 trials in 1 country | No |
| GEMCOVAC-19 | Gennova Biopharmaceuticals Limited | RNA | Approved in 1 country | 2 trials in 1 country | No |
| Covifenz | Medicago | RNA | Approved in 1 country | 6 trials in 6 countries | No |
| Spikevax | Moderna | RNA | Approved in 88 countries | 70 trials in 24 countries | Yes |
| Spikevax Bivalent Original/Omicron BA.1 | Moderna | RNA | Approved in 38 countries | 5 trials in 4 countries | No |
| Spikevax BivalentOriginal/Omicron BA.4/BA.5 | Moderna | RNA | Approved in 33 countries | 2 trials in 1 country | No |
| Comirnaty (BNT162b2) | Pfizer/BioNTech | RNA | Approved in 149 countries | 100 trials in 31 countries | Yes |
| Comirnaty Bivalent Original/Omicron BA.1 | Pfizer/BioNTech | RNA | Approved in 35 countries | 3 trials in 5 countries | No |
| Comirnaty Bivalent Original/Omicron BA.4/BA.5 | Pfizer/BioNTech | RNA | Approved in 33 countries | 4 trials in 1 country | No |
| TAK-919 (Moderna formulation) | Takeda | RNA | Approved in 1 country | 2 trials in 1 country | No |
| AWcorna | Walvax | RNA | Approved in 1 country | 6 trials in 1 country | No |
| Covaxin | Bharat Biotech | Inactivated Virus | Approved in 14 countries | 16 trials in 2 countries | Yes |
| KoviVac | Chumakov Center | Inactivated Virus | Approved in 3 countries | 3 trials in 1 country (No trials for Phase 3) | No |
| Turkovac | Health Institutes of Turkey | Inactivated Virus | Approved in 1 country | 8 trials in 1 country | No |
| FAKHRAVAC (MIVAC) | Organization of Defensive Innovation and Research | Inactivated Virus | Approved in 1 country | 3 trials in 1 country | No |
| QazVac | Research Institute for Biological Safety Problems (RIBSP) | Inactivated Virus | Approved in 2 countries | 3 trials in 1 country | No |
| KCONVAC | Shenzhen Kangtai Biological Products Co | Inactivated Virus | Approved in 2 countries | 7 trials in 1 country | No |
| COVIran Barekat | Shifa Pharmed Industrial Co | Inactivated Virus | Approved in 1 country | 6 trials in 1 country | No |
| Covilo | Sinopharm (Beijing) | Inactivated Virus | Approved in 93 countries | 39 trials in 18 countries | Yes |
| Inactivated (Vero Cells) | Sinopharm (Wuhan) | Inactivated Virus | Approved in 2 countries | 9 trials in 7 countries | No |
| CoronaVac | Sinovac | Inactivated Virus | Approved in 56 countries | 42 trials in 10 countries | Yes |
| VLA2001 | Valneva | Inactivated Virus | Approved in 33 countries | 9 trials in 4 countries | No |
| iNCOVACC | Bharat Biotech | Non-Replicating Viral Vector | Approved in 1 country | 4 trials in 1 country | No |
| Convidecia | CanSino | Non-Replicating Viral Vector | Approved in 10 countries | 14 trials in 6 countries | Yes |
| Convidecia Air | CanSino | Non-Replicating Viral Vector | Approved in 2 countries | 5 trials in 4 countries | No |
| Gam-COVID-Vac | Gamaleya | Non-Replicating Viral Vector | Approved in 1 country | 2 trials in 1 country (No trials for Phase 3) | No |
| Sputnik Light | Gamaleya | Non-Replicating Viral Vector | Approved in 26 countries | 7 trials in 3 countries | No |
| Sputnik V | Gamaleya | Non-Replicating Viral Vector | Approved in 74 countries | 25 trials in 8 countries | No |
| Jcovden | Janssen (Johnson & Johnson) | Non-Replicating Viral Vector | Approved in 113 countries | 26 trials in 25 countries | Yes |
| Vaxzevria | Oxford/AstraZeneca | Non-Replicating Viral Vector | Approved in 149 countries | 73 trials in 34 countries | Yes |
| Covishield (Oxford/AstraZeneca formulation) | Serum Institute of India | Non-Replicating Viral Vector | Approved in 49 countries | 6 trials in 1 country | Yes |
| Covifenz | Medicago | Virus-like Particles (VLP) | Approved in 1 country | 6 trials in 6 countries | No |
| ZyCoV-D | Zydus Cadila | DNA | Approved in 1 country | 6 trials in 1 country | No |